ARTICLE | Company News
J&J, Merck KGaA deal
July 14, 2003 7:00 AM UTC
Biovation, a MRK company, will apply its DeImmunisation technology to undisclosed therapeutic proteins from JNJ subsidiary Centocor. DeImmunisation technology is designed to eliminate or reduce T cell...